XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1
ASSETS AND LIABILITIES HELD FOR SALE
 6 Months Ended
Jun. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]  
ASSETS AND LIABILITIES HELD FOR SALE ASSETS AND LIABILITIES HELD FOR SALE
On May 7, 2024, the Company signed a definitive agreement to sell its EndoPredict business to Eurobio Scientific ("Eurobio") for $10.0 million, subject to customary closing adjustments, plus contingent consideration subject to certain earn-out conditions. As part of the transaction, the Company will license the rights to continue to produce and sell EndoPredict as a laboratory developed test outside of the European Union and will license to Eurobio the right to sell Prolaris in vitro diagnostic kits outside the U.S. The sale of the EndoPredict business closed on August 1, 2024.
The Company measured the Endopredict business at the lower of its carrying value less costs to sell and recognized an impairment on held for sale assets of $10.2 million during the quarter ended June 30, 2024. The impairment expense is recorded in Goodwill and long-lived asset impairment charges in the Condensed Consolidated Statements of Operations.
The operating results of the EndoPredict business do not qualify for reporting as discontinued operations. The operations of the EndoPredict business are included in the Company's testing revenue. The following table presents information related to the assets and liabilities classified as held for sale at June 30, 2024:
(in millions)Total
Assets
Cash
$2.3 
Accounts Receivable
1.6 
Inventory1.6 
Intangibles, net13.1 
Other assets1.6 
Total assets held for sale$20.2 
Less valuation allowance
(9.8)
Total assets held for sale
$10.4 
Liabilities
Other liabilities$4.0 
Total liabilities held for sale$4.0 
Total net assets held for sale$6.4